KR20120111123A - Composition for treatment of pancreatic cancer and functional food comprising extract of circii radix - Google Patents

Abstract

PURPOSE: A composition and a functional food containing Circii Radix ethanol extract is provided to effectively prevent and treat pancreatic cancer. CONSTITUTION: A composition for preventing and treating pancreatic cancer contains Circii Radix ethanol extract as an active ingredient. The composition also contains pharmaceutically acceptable carriersor diluents. A functional food for preventing pancreatic cancer contains 0.1-5 wt% of the extract as an active ingredient. [Reference numerals] (AA) Relative cell survival rate

Description

Composition for Treatment of Pancreatic Cancer and Functional Food Comprising Extract of Circii Radix}

The present invention relates to a novel use of the extract of Rhizome root. Specifically, the present invention relates to a therapeutic composition and a functional food containing the extract as an active ingredient, which has an excellent preventive or therapeutic effect against pancreatic cancer.

Among the major diseases of modern people, researches on the treatment and diagnosis of cancer are relatively active, mainly in lung cancer, liver cancer, gastric cancer, and the like. However, studies on esophageal cancer, colorectal cancer, and pancreatic cancer with low incidence are relatively low.

The pancreas produces insulin, which helps the body convert glucose into energy, and enzymes that help the body digest food. Pancreatic cancer is a malignant growth of the pancreas, mainly occurring in cells of the pancreatic duct. The disease is the ninth most common form of cancer, but it is the fourth and fifth most common cause of cancer deaths in men and women, respectively. Pancreatic cancer has a five-year survival rate of less than 3%, most of which is always fatal. Pancreatic ductal adenocarcinoma (pancreatic ductal adenocarcinoma) in the pancreatic cancer, which accounts for more than 90% of pancreatic cancer generally refers to pancreatic adenocarcinoma. Pancreatic adenocarcinoma is also called pancreatic adenocarcinoma, pancreatic adenocarcinoma, or pancreatic adenocarcinoma.

 Like many other malignant diseases, pancreatic cancer arises from the accumulation of acquired mutations. Multiple genetic and epigenetic changes, including activation of protocogenes, inactivation of tumor suppressor genes, and malformations of maintenance genes, may result in the development, sustained growth, and metastasis of pancreatic cancer. Related to Accumulated mutations in such genes are known to occur within predictable time during the "PanINs" (Pancreatic Intraepithelial Neoplsia) phase (Hruban et al. (2000) Clin Cancer Res 6: 2969-2972; Kern (2002) Cancer Biol Therapy 1: 607-613; Li et al. (2004) Lancet 363: 1049-1057). K-ras mutations occur about half of PanIN-1. The PanIN-2 stage is represented by additional changes and increases in the rate of K-ras mutations, and the appearance of multiple p16 malformations, and p53 protein family expression, which may indicate the presence of p53 mutations, is sometimes seen in more advanced PanINs. Loss of the tumor suppressor genes, TP53, DPC4 and BRCA2, appears to occur late in the development of pancreatic tumorigenesis, PanIN-3. Specifically, more than 85% of pancreatic adenocarcinomas have K-ras gene point mutations activated in pancreatic cancer development (Li et al. (2004) Lancet 363: 1049-1057; Xiong (2004) Cancer Chem Pharm 54: S69-77). K-ras mutations induce constitutive activation of Ras-Raf-MEK-ERK, an intracellular signaling pathway that induces cell proliferation and confers transgene properties on cells containing point mutations. Cause. Ras mutations are not associated with tumor stage or prognosis, and indicate that the K-ras oncogene may be involved in the onset of carcinogenesis but not in the likelihood or promotion of human pancreatic cancer. One of the major downstream targets of the ras family is phosphoinositol 3 kinase (PI3K). Activation of PI3K is associated with pancreatic cancer resistance to apotosis induced by chemotherapy or molecular drug targeting agents.

Pancreatic adenocarcinoma is one of the most deadly human malignancies with more than 30,000 deaths annually in the United States alone. At diagnosis these cancers are found in a state where only 10% to 15% can be excised due to the presence of locally advanced disease or distant metastasis. Recently, the most common treatment strategy for advanced pancreatic cancer is gemcitabine, a 2'-deoxycytidine nucleoside analogue for intravenous administration that can induce apoptosis of human pancreatic cancer cells and inhibit tumor growth and progression. It is a treatment by. However, despite the best medical or surgical treatment, the results of treatment of patients with pancreatic adenocarcinoma are terrible, and as a group, the median survival of patients with this disease is 21 months or less. Thus, there is a need for clear, new and efficient treatment strategies to combat this deadly disease. As such, pancreatic cancer is a major health issue in developed countries and has a very poor prognosis (Faint et al. (2004) Datamonitor DMHC2045; Garcea et al. (2005) Pancreatology 5: 514-529; Kern et al. (2002). ) Cancer Biol Therapy 1: 607-613; Laheru and Jaffee (2005) Nature Rev Cancer 5: 59-467; Li et al. (2004) Lancet 363: 1049-1057). Despite excessive surgical and medical treatment, the mean life expectancy is about 15-18 months for patients with local disease and 3-6 months for patients with metastatic disease. Nearly 100% of patients with pancreatic cancer experience metastasis and die due to their unrestricted growth, which weakens metabolism, and less than 5% of patients who have not undergone resection survive a total of 5 years. Do. In addition, there is a problem that the initial diagnosis is difficult due to the non-specific initial symptoms. Currently, early detection of pancreatic cancer is still under development and not commercially available, and conventional cancer treatments have little effect on prognosis or disease outcome. Poor prognosis for pancreatic cancer is due to late manifestation, aggressive local invasion, early metastasis and insufficient response to chemotherapy.

The most common symptoms of pancreatic cancer include jaundice, abdominal pain and weight loss, and are not substantially special along with other emergence factors. Thus, diagnosing pancreatic cancer at an early stage of tumor growth is often difficult and requires a situation that includes considerable doubt and extensive diagnostic overhauls, often exploratory surgery. Endoscopic ultrasonography and computed tomography (CT) are the best noninvasive methods currently available for diagnosing pancreatic cancer. However, as well as differentiation of pancreatic cancer from lesioned pancreatitis, reliable detection of small tumors is difficult. Unfortunately, the majority of patients are currently diagnosed at a late stage where the tumor has already invaded the surrounding organs, extending outward and / or extensively metastasized (Gold et al., Crit. Rev. Oncology / Hematology, 39: 147-54 (2001). The disease is late detection is common, and early diagnosis of pancreatic cancer is rare in clinical settings.

Currently available treatment methods for pancreatic cancer do not cure the disease or reach a substantially improved survival time. Surgical resection is the only way to provide survival. However, due to tumor burden, only 10-25% of patients are targeted for 'curative resection'. In these patients undergoing resection treatment, the 5-year survival rate is still on average at around 10%.

Circii Radix , on the other hand, is the root of the coriander plant Cirsium japonicum DC. This is used for the treatment of boils and for hemostasis such as uterine bleeding, hemorrhage and nosebleeds. However, nothing has been disclosed or disclosed in this document with respect to pancreatic cancer-related diseases of the paraglia.

Accordingly, the present inventors completed the present invention by confirming that the extract of the Greater Root can effectively kill the pancreatic cancer cells during the herbal research on the Greater Root.

It is an object of the present invention to provide a composition for treating pancreatic cancer and a functional food containing the extract of R. ginseng as an active ingredient.

In order to achieve the above object, the present invention provides a composition for the prevention and treatment of pancreatic cancer containing Circii Radix ethanol extract as an active ingredient.

In another aspect, the present invention provides a functional food for preventing pancreatic cancer containing Circii Radix ethanol extract containing a food supplement acceptable food additive as an active ingredient.

 Hereinafter, the present invention will be described in detail.

The present invention provides a composition for preventing and treating pancreatic cancer, which comprises Circii Radix ethanol extract as an active ingredient. The composition of the present invention includes the extract of the Greater Root as an active ingredient, and may further include a pharmaceutically acceptable carrier or diluent.

In the composition for preventing and treating pancreatic cancer of the present invention, the ethanol extract is preferably extracted for 24 hours at 50 ℃, wherein the ethanol extract is more preferably dried and concentrated at 45 ℃ reduced pressure conditions, the ethanol is Most preferred is 95%.

In addition, in the composition for preventing and treating pancreatic cancer of the present invention, the pancreatic cancer is preferably pancreatic ductal adenocarcinoma.

The extract of Greater Root of the present invention is possible at any site of the Greater Root, but is preferably extracted from the root. The extraction solution may be obtained by extraction with water or an organic solvent, and examples of the organic solvent may include lower alcohols, acetone, chloroform, methylene chloride, ether, ethyl acetate, and hexane. Lower alcohols include methanol, ethanol, propanol and butanol, with ethanol being most preferred.

Specifically, 1 to 5 times, preferably 3 times, 95% ethanol is added to the dried or powdered grandiose root and 10 to 100 hours, preferably 15 at a temperature of 20 to 100 ° C, preferably 40 to 60 ° C. To 40 hours, more preferably, 24 hours after the extraction can be filtered to prepare the ethanol extract of the cockerel root. Preferably, the filtrate obtained by filtering the extract may be concentrated under reduced pressure. In the above extraction methods, the extraction process may be repeated two or more times as necessary, and the extract obtained after filtration may be lyophilized or dried under reduced pressure to obtain a powder form.

The "pharmaceutically acceptable carrier" is a pharmaceutically acceptable substance such as a liquid or solid filler, diluent, excipient or solvent which serves to transport the active ingredient from one organ or part of the body to another organ or part of the body. , Composition or vehicle.

The composition for treating pancreatic cancer of the present invention may be prepared as a medicament by adding one or more pharmaceutically acceptable carriers together with the active ingredient. The carrier may include, but is not limited to, saline, buffered saline, water, glycerol and ethanol, and any suitable agent known in the art (Remingtons's Pharmaceutical Science (Recent Edition), Mack Publishing Company, Easton PA) may be used. .

Formulation for pharmacological extract of the present invention can be administered orally during clinical administration and can be used in the form of a general pharmaceutical formulation, when formulated, commonly used fillers, extenders, binders, wetting agents, disintegrant And diluents such as surfactants or excipients. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and liquid preparations for oral use include suspensions, solvents, emulsions, and syrups. In addition to liquids and paraffins, various excipients may be included, such as wetting sweeteners, fragrances, preservatives and the like.

In addition, the herbal medicine that may be added to the composition of the present invention may be any pharmaceutically acceptable herbal medicine, for example, Angelica tenuissimae Radix, Gastrodiae Rhizoma, Bapleuri Radix, Angelica ( Angelicae gigantis Radix, Persicae Semen, Cinnamomi Ramulus, Rhubarb (Rhei Rhizoma), Licorice (Glycyrrhizae Radix), Cnidii Rhizoma, Aurantii nobilis Pericarpium, Taxa (Alismatis Rhizoma) Coptidis Rhizoma, Scutellariae Radix, Hoelen, Peeoniae Radix, Atractylodis Rhizoma alba, Phellodendri Cortex, Gardeniae Fructus, Pinelliae Tuber, Ramulu Set (Uncaria) Uncus, Ponciri Fructus, Ginseng (Gingseng), Liriopis Tuber, Polygalae Radix, Acori graminei Rhizoma, Atractylodis Rhizoma alba, Chrysanthemi Flos, Windproof (Ledebouri) ), Ginger (Meliae Cortex crudus), forget-me-not (Natrii sulfas), control (Zizyphi) Fructus, Salviae Radix, Mautan Radicis Cortex, Rehmanniae Radix, Minthae Herba, Dioscoreae Rhizoma, Polyporus, Polygoni multiflori Radix, Gumen (Allii tuberosi Se) ), Cassiae Semen, Lycii Fructus, Araliae cordatae Radix, Eucommiae Cortex, Hedyotis Herba, Saururus Herba, Artemisiaecapillaris Herba, Jimo Rhiemarrhenae ), Safflower (Carthami Flos), Astragali Radix, Lycopodium, Ginkgois Folium, Polygonati Rhizoma, Nelumbinis Semen, Fossilia ossis Mastodi, Lycoii radicis Cortex , Achyranthis Radix, Rehmanniae Radix preparata, Perillae Semen, Thujae Semen, Malt (Hordei Fructus germinatus), Cuscutae Semen, Morindae Radix, Pear koraiensis ) May be used alone or in combination.

The composition of the present invention may be administered in various parenteral formulations during actual clinical administration, and solid preparations include tablets, pills, powders, granules, capsules, and the like. In addition to water, liquid, and paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included. Specifically, preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. Propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used as the non-aqueous solvent and suspension agent. Examples of the suppository base include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like. In addition, calcium or vitamin D ₃ may be added to enhance the efficacy of the treatment. Such compositions may be presented in unit-dose (single) or multi-dose (several) containers, such as sealed ampoules and vials, and immediately before use, sterile liquid carriers such as injectable water. Can be stored under freeze-drying conditions requiring only the addition of. Immediate injection solutions and suspensions can be prepared from sterile powders, granules and tablets.

The formulations of the present invention can be applied differently depending on the age, sex, condition of the subject, the absorption of the active ingredient in the body, the inactivation rate and excretion rate, the drug used in combination. The invention also includes formulations of dosage units. The formulations are present in individual dosage forms, such as tablets, coated tablets, capsules, pills, suppositories, and ampoules, wherein the amount of active compound in the drug corresponds to the fraction or multiple of the individual dosage. Dosage units may contain, for example, one, two, three or four times the individual dosage, or 1/2, 1/3 or 1/4 times. The individual dosages preferably contain an amount in which the active compound is administered at one time, which usually corresponds to all, 1/2, 1/3 or 1/4 times the daily dosage.

As used herein, the term "extract" refers to an active ingredient isolated from natural products. The extract may be obtained by an extraction process using water, an organic solvent, or a mixed solvent thereof, and includes an extract, a dry powder thereof, or any form formulated using the same.

In a specific embodiment of the present invention, the ethanol extract of Escherichia coli kills 94.8% of Panc-1 pancreatic cancer cells at 100 μg / ml and the EC ₅₀ (half maximal effective concentration) is 63.4 μg / ml. The above results demonstrate that the extract of the present invention has excellent killing activity of Panc-1 pancreatic cancer cells and further has pancreatic cancer treatment and prophylactic activity.

As used herein, the term "prevention" means any action that inhibits or delays the development of pancreatic cancer by administration of the composition.

As used herein, the term "treatment" means any action that improves or beneficially alters the symptoms of pancreatic cancer by administration of the composition.

In the present invention can be used to extract the geunyeogeun extract using water, an organic solvent, or a mixed solvent thereof. Preferably it is extracted using an organic solvent, in particular ethanol. The extracted solution can be used directly or can be concentrated and / or dried. When extracted with an organic solvent, methanol, ethanol, isopropanol, butanol, ethylene, acetone, hexane, ether, chloroform, ethyl acetate, butyl acetate, dichloromethane, N, N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), 1,3-butylene glycol, propylene glycol, or a mixed solvent thereof may be used and extracted by room temperature or warming under conditions where the active ingredient of the herbal medicine is not destroyed or minimized. Depending on the organic solvent to be extracted, the degree of extraction and loss of the active ingredient of the drug may vary, so select an appropriate organic solvent. The extraction method is not particularly limited, and examples thereof include cold needle extraction, ultrasonic extraction, reflux cooling extraction, and the like. Filtration is a process of removing the suspended solid particles from the extract, it may be used to filter the particles using cotton, nylon or the like, or may be used, such as ultrafiltration, cryofiltration, centrifugal separation, but is not limited thereto.

Concentration of the extract may be used, such as concentrated under reduced pressure, reverse osmosis concentration. The drying step after concentration includes freeze drying, vacuum drying, hot air drying, spray drying, reduced pressure drying, foam drying, high frequency drying, infrared drying, and the like. If desired, a process of grinding the final dried extract may be added.

In addition, the extract can perform an additional fractionation process. Preferably, the extract is suspended in distilled water to obtain a nonpolar solvent soluble layer by extraction and separation with a nonpolar organic solvent such as hexane, ether, dichloromethane, chloroform, ethyl acetate, or a mixed solvent thereof. It can be used by concentrating and / or drying it.

In the present invention, the term "pharmaceutically acceptable salts" means salts derived from pharmacologically or physiologically acceptable inorganic acids, organic acids and bases. Examples of suitable acids include hydrochloric acid, bromic acid, sulfuric acid, nitric acid, perchloric acid, fumaric acid, maleic acid, phosphoric acid, glycolic acid, lactic acid, salicylic acid, succinic acid, toluene-p-sulfonic acid, tartaric acid, acetic acid, citric acid, methanesulfonic acid, formic acid , Benzoic acid, malonic acid, naphthalene-2-sulfonic acid, benzenesulfonic acid, and the like. Salts derived from suitable bases may include alkali metals such as sodium, alkaline earth metals such as magnesium, ammonium and the like.

The pharmaceutical composition for preventing and treating pancreatic cancer diseases of the present invention comprises 0.1 to 50% by weight of the extract or compound based on the total weight of the composition. In addition, the composition does not increase the efficacy, but may include additional ingredients that are commonly used in the pharmaceutical composition to improve the smell, taste, time and the like. In addition, the composition adds inorganic and organic additives such as vitamins B1, B2, B6, C, E, niacin, carnitine, betaine, folate pantothenic acid, biotin, zinc, iron, calcium, chromium, magnesium, and mixtures thereof. It can be included as. In addition, the composition may include a substance having a therapeutic activity against pancreatic cancer, used alone or previously used.

As used herein, the term "patient" refers to humans and horses, sheep, pigs, goats, camels, who have diseases caused by pancreatic cancer and its direct and indirect causes, and whose symptoms may be improved by administering the composition of the present invention. Means antelope, dog and other animals. By administering to a patient a composition comprising the extract of the Greater Root of the present invention, the above-mentioned pancreatic cancer can be effectively prevented and treated. The composition of the present invention can be administered in parallel with existing pancreatic cancer therapeutics.

As used herein, the term "administration" means introducing a predetermined substance into a patient by any suitable method, and the route of administration of the composition of the present invention is oral or parenteral via any general route as long as the target tissue can be reached. May be administered. In addition, the composition may be administered by any device in which the active agent may migrate to the target cell.

The composition of the present invention is administered in a pharmaceutically effective amount. As used herein, the term “pharmaceutically effective amount” means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and an effective dose level refers to a patient's sexually transmitted disease, age, severity, and drug activity. , Drug sensitivity, time of administration, route of administration and rate of release, duration of treatment, factors including concurrently used drugs, and other factors well known in the medical arts. The compositions of the present invention may be administered as individual therapeutic agents or in combination with other therapeutic agents and may be administered sequentially or simultaneously with conventional therapeutic agents. It may be single or multiple doses. It is important to take into account all of the above factors and to administer the amount in which the maximum effect can be obtained in a minimal amount without adverse effect, and can be easily determined by those skilled in the art. The method of administering the composition comprising the extract or compound prepared according to the preparation method of the present invention is preferably oral administration or intravenous administration. In general, when the effective dose is oral administration, it is usually 1 to 1 time per adult. 500 mg / kg is preferred, and in the case of intravenous administration, 1 to 100 mg / kg is preferred, and may be administered 2-3 times a day. Dosage levels for a particular patient may vary depending on sex, age, health condition, diet, time of administration, method of administration, drug mixture, the condition of the patient, and the extent of the onset of neurological disease.

In another aspect, the present invention provides a functional food for preventing pancreatic cancer containing Circii Radix ethanol extract containing a food supplement acceptable food additive as an active ingredient.

Functional food of the present invention preferably contains 0.1 to 5% by weight, more preferably 1% by weight of the ethanol extract relative to the total weight. Functional food of the present invention is not particularly limited in the formulation, for example, dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, ice cream, Various soups, beverages, tea, drinks, alcoholic beverages and vitamin complexes, etc., and includes all of the health food in the usual sense.

In the present invention, "functional food" means a food manufactured and processed using raw materials or ingredients having functional properties useful for the human body according to Act No. 6767 of the Health Functional Food Act, and "functional" refers to the structure of the human body And ingestion for the purpose of obtaining nutrients for function or for obtaining useful effects in health uses such as physiological actions.

In the present invention, when the extract of the present invention is added to Panc-1 pancreatic cancer cells, it was confirmed that Panc-1 pancreatic cancer cells were killed (see FIG. 1 ). Therefore, it can be seen that the extract of R. ginseng has a therapeutic effect on pancreatic cancer. Thus, in the present invention, the present invention was completed by preparing a functional food for preventing pancreatic cancer, which contains the extract of Greater Root as an active ingredient (see Preparation Example 2 ).

As described above, the root extract of the present invention inhibits the growth of pancreatic cancer cells and induces apoptosis. Therefore, the composition for treating pancreatic cancer according to the present invention will be very effective for the treatment of pancreatic cancer patients.

1 is a result of Alamar Blue analysis to determine the effect of the introduction of the Greater Root muscle on the growth of pancreatic cancer cells in Panc-1 cells, which are human pancreatic cancer cells. The viability of the cells is shown.

Hereinafter, the present invention will be described in more detail based on the following examples. It should be noted, however, that the following examples are for illustrative purposes only and are not intended to limit the scope of the present invention. The present invention is not limited to the following examples. Will be apparent to those skilled in the art to which the present invention pertains.

Example 1 Preparation of Root Extract

3 kg of Daegye-geun (domestic) purchased from Seoul medicinal herb was dried and ground for 5 days at room temperature and room temperature. The crushed giant root was soaked in 30 L of 95% ethanol and extracted at 50 ° C. for 24 hours. It was filtered through filter paper, dried and concentrated under reduced pressure at 45 ° C. to obtain 481 g of the total extract, and stored at −20 ° C.

Example 2 Effect of Escherichia coli Extract on the Growth of Pancreatic Cancer Cells

In order to determine the effect of the extract of C. aeruginosa extract in Example 1 on the growth of pancreatic cancer cells, Panc-1 cells, which are human pancreatic cancer cells, were treated with ethanol extract of C. aeruginus for 48 hours and subjected to Alamar Blue analysis. The Alamar Blue assay is a modified form of the MTT assay, in which a specific enzyme degrades a living cell and then measures the fluorescence intensity of the product as the compound breaks down to determine the relative number of living cells after treatment. I am an experimental method. It will be described in more detail below.

<2-1> Preparation and Treatment of Human Pancreatic Cancer Cell Lines

Panc-1 cells, a pancreatic cancer cell line used in the present invention, were distributed from the Korean Cell Line Bank (KCLB) and used for experiments. Specifically, Panc-1 pancreatic cancer cells are DMEM (Dulbeco's Modified Eagle's) containing 10% FBS (fetal bovine serum, fetal bovine serum) (Welgene) and 25 mM HEPES (4- (2-hydroxyethyl) -1-piperazineethanesulfonic acid) Medium) was passaged in medium.

<2-2> Inhibition of Cell Growth in Panc-1 Pancreatic Cancer Cells

Checked the effect of inhibiting the growth of Pancreatic cancer cells, the pancreatic cancer extract extracted in Example 1 the pancreatic cancer cells. Specifically, 4.5 × 10 ³ Panc-1 pancreatic cancer cells per well were seeded in a 96 well plate, incubated for 24 hours, and then dissolved in DMSO (Dimethyl sulfoxide). When the ethanol extract was treated at concentrations of 0 to 100 μg / ml (specifically, concentrations of 0, 3.125, 6.25, 12.5, 25, 50, and 100 μg / ml, respectively) for 48 hours, the degree of inhibition of cell growth was confirmed. (Table 1). After treatment with each concentration of extract, 20 μl of Alamar Blue reagent was added to 0.2 ml of cell culture filled in each well in a 96-well plate, and the plates were incubated for 2 hours in an incubator. The plate was slowly shaken to evenly react the cells of each well, and the intensity of fluorescence was measured at 590 nm with a Fluorescence Microplate Reader (Molecular Devices Corp.) while irradiating irradiated light at a wavelength of 544 nm. Survival is shown in FIG.

Root muscle concentration Pancreatic cancer cell survival rate (average) Standard Deviation 0 μg / ml 1,000 0.000 3.125 μg / ml 1.066 0.071 6.25 μg / ml 0.925 0.019 12.5 μg / ml 0.929 0.056 25 μg / ml 0.904 0.043 50 [mu] g / ml 0.814 0.061 100 μg / ml 0.052 0.008

As a result, as shown in Table 1 and Figure 1, the higher the treatment concentration of the cockerel muscle, the growth of pancreatic cancer cells was reduced, from which it can be seen that the cockerel muscle has a pancreatic cancer treatment effect. That is, pancreatic cancer cells were killed at 7.5% at 6.25 μg / ml, 7.1% at 12.5 μg / ml, 19.6% at 25 μg / ml, 18.6% at 50 μg / ml, and 94.8% at 100 μg / ml. In addition, the EC ₅₀ (half maximal effective concentration) was determined to be 63.4 μg / ml. Table 1 above describes the relative cell numbers of pancreatic cancer cells after 48 hours according to the respective concentration levels of the pancreatic cancer, based on the number of survival rates of the pancreatic cancer cells of the control group that was not treated with the paragonal muscle. As such, the extract of the present invention has excellent Panc-1 cell killing activity and further demonstrates pancreatic cancer treatment and prophylactic activity.

Example 3 Acute Toxicity Test with Escherichia coli Extract

Since the colic root used in the present invention was widely used as a medicinal herb, it was determined that there was no problem in stability, but the oral administration and the intraperitoneal administration were performed to confirm the toxicity.

Acute toxicity test was performed using 6-week-old SPF SD rats. Two animals per group were suspended orally administered at a dose of 5 g / kg in suspension of the root of the extract of Example 1 of the present invention in 0.5% methylcellulose solution. After administration of the test substance, mortality, clinical symptoms, and changes in body weight were observed, and hematological and hematological examinations were performed.

As a result, there were no clinical symptoms or deaths in all animals treated with the test substance, and no toxicity change was observed in weight change, blood test, blood biochemistry test, autopsy findings, etc. As a result, all extracts of Geun-geun did not show toxic changes up to 5 g / kg in rats and the minimum lethal dose (LD ₅₀ ) was determined to be a safe substance of 5 g / kg or more.

Preparation Example 1 Preparation of a Pancreatic Cancer Therapeutic Agent Containing Extract of Geun-Geun as an Active Ingredient

The present inventors have confirmed that the pancreatic cancer treatment efficacy of the extract of the Greater Root of Pancreas through the above embodiment was prepared as a pancreatic cancer therapeutic agent containing the Greater Root Extract as an active ingredient as follows. In addition, the preparation of the following therapeutic agent can be used for the application of not only a therapeutic agent but also a health food.

<1-1> Soft Gelatin Capsules Containing Root Extract

Escherichia coli extract 20%

Vitamin C 4.5%

Vitamin D ₃ 0.001%

Manganese Sulfate 0.1%

10% wax

Palm oil 25%

Safflower Seed Oil 30.399%

 <1-2> Preparation of Intravenous Formulation Containing Root Extract

Escherichia coli extract 0.2%

Mannitol 0.3%

Saline 9.5%

<1-3> tablet containing extract

Escherichia coli extract 35%

Vitamin C 10%

Vitamin D ₃ 0.001%

Manganese Sulfate 0.1%

Crystalline cellulose 25.0%

Lactose 17.999%

Magnesium Stearate 2%

Preparation Example 2 Preparation of Functional Foods Containing Greater Root Extract as Active Ingredients

The inventors have confirmed that the extract of the Greater Rheum antagonist has excellent pancreatic cancer therapeutic activity through the above examples, and prepared functional foods containing the same as an active ingredient as follows.

<2-1> Preparation of Drink

522 mg of honey

Chioctosanamide 5 mg

Nicotinamide 10 mg

Riboflavin Sodium Hydrochloride 3 mg

Pyridoxine hydrochloride 2 mg

Inositol 30 mg

Orthoic acid 50 mg

Large Root Extract 0.48 ~ 1.28 ㎎

200 ml of water

A beverage was prepared using the above-mentioned composition and content by a conventional method.

<2-2> production of chewing gum

Gum base 20%

Sugar 76.36-76.76%

Escherichia coli extract 0.24 ~ 0.64%

1% fruit flavor

Water 2%

Chewing gum was prepared using the above-mentioned composition and content by a conventional method.

<2-3> Preparation of Candy

Sugar 50-60%

Starch syrup 39.26 ~ 49.66%

Escherichia coli extract 0.24 ~ 0.64%

Orange flavor 0.1%

The composition and the content of the candy were prepared using a conventional method.

<2-4> Preparation of Biscuits

Force Class 1 88 kg

Gravity First Class 76.4 ㎏

16.5 kg

2.5 kg of salt

2.7 kg of glucose

Palm shortening 40.5 kg

5.3 kg of ammo

Medium kg 0.6 kg

0.55 kg sodium bisulfite

Rice flour 5.0 kg

Vitamin B1 0.003 kg

0.003 kg of vitamin B2

Milk Flavor 0.16 ㎏

71.1 kg of water

Whole milk powder 4 kg

Substitute powder 1 kg

0.1 kg of calcium phosphate

Spray salt 1 kg

25 kg of spray oil

Escherichia coli extract 0.2-0.5 kg

Biscuits were prepared using conventional methods with the above composition and content.

<2-5> Preparation of Ice Cream

Milkfat 10.0%

Non-fat solids 10.8%

Sugar 12.0%

Starch syrup 3.0%

Emulsifying stabilizer (span) 0.5%

Spices (Strawberries) 0.15%

Water 63.31 ~ 62.91%

Escherichia coli extract 0.24 ~ 0.64%

Ice cream was prepared using conventional methods using the above composition and content.

<2-6> manufacturing of chocolate

Sugar 34.36-34.76%

Cocoa Butter 34%

Cocoa Mass 15%

Cocoa Powder 15%

Lecithin 0.5%

0.5% vanilla

Escherichia coli extract 0.24 ~ 0.64%

With the above composition and content, chocolate was prepared using conventional methods.

On the other hand, the specific scope of the present invention is defined by the claims rather than the embodiments described above, all changes and modifications derived from the meaning and scope and equivalent concepts of the claims to the scope of the invention It should be interpreted as including.

Claims (7)

A composition for preventing and treating pancreatic cancer, comprising circii radix ethanol extract as an active ingredient.
According to claim 1, wherein the ethanol extract is a composition for preventing and treating pancreatic cancer, characterized in that extracted for 24 hours at 50 ℃.
The pancreatic cancer prevention and treatment composition according to claim 1 or 2, wherein the ethanol extract is dried and concentrated under a reduced pressure of 45 ° C.
According to claim 1 or 2, wherein the ethanol is a composition for the prevention and treatment of pancreatic cancer, characterized in that 95%.
The composition for preventing and treating pancreatic cancer according to claim 1, wherein the composition comprises a pharmaceutically acceptable carrier or diluent.
According to claim 1, wherein the pancreatic cancer is pancreatic ductal adenocarcinoma (pancreatic ductal adenocarcinoma) composition for the prevention and treatment of pancreatic cancer.
A functional food for preventing pancreatic cancer, comprising as an active ingredient Circii Radix ethanol extract containing a food supplement acceptable food additive.

Images